All News

CAR-T

From Skepticism to Reconsideration: 4‑Year CAR‑T Outcomes in Lupus

Bella Mehta, MBBS, MS

Chimeric antigen receptor (CAR) T‑cell therapy, long established in hematologic malignancies, is now emerging as a transformative approach in systemic lupus erythematosus (SLE), a disease historically managed with chronic immunosuppression.

Read Article
lupus.jpg

Progress of biologics/targeted therapy in SLE

Md Yuzaiful Md Yusof, MRCP(UK), PhD

We are in a transformative era in SLE which generates excitement to both physicians and people living with lupus. We now have four licensed biologics/targeted therapies (i.e., belimumab, voclosporin and obinutuzumab for active lupus nephritis, and belimumab and anifrolumab for active non-renal SLE). Moreover, many other agents with different mode of action and administration are in late phase trials. This article previews some data being presented at EULAR 2026 Congress in London.

Read Article
elderly hands

A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology

Jiha Lee, MD

A substantial portion of patients seen in rheumatology clinics are now older adults living with multimorbidity, polypharmacy, frailty, cognitive impairment, functional limitation, and competing health priorities. This week at EULAR 2026 in London, the EULAR Study Group on Geriatric Rheumatology holds its inaugural meeting. The launch marks an important step for a field that has been visible in clinical practice, but less visible in professional structures.

Read Article
APR video gout cover

Gout

Jack Cush, MD

Dr. Jack Cush reviews Gout in this continuing series for Advanced Practice Rheum. Review the companion slide deck here.

Read Article
SLE & Dengue infxn? This pop’n study from Brazil showed that #SLE pts who developed #dengue had sig. higher rates of mortality, DHF & hospital stay length vs. gen popn These factors were found to have strong independent assoc w/SLE. Abs010 @rheumnow #EULAR2026 https://t.co/DTDPiQRlAf

Links:

sheila RHEUMarampa ( View Tweet)
IL-23i vs IL-17i in PsABIOnd (n=1,141): 12mo persistence (~77%), joint/skin response, MDA, and PROs similar across both. GUS matched IL-17i despite treating more biologic-experienced pts (15% vs 8% on 4th-line). GI AEs higher with IL-17i (11% vs 7%). @RheumNow #EULAR2026 POS0045

Jiha Lee JihaRheum ( View Tweet)

What’s new in (WIN) PsA session. A preview of the BE BOLD study: Bimekizumab vs risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.008). The first head-to-head biologic trial to show joint superiority in PsA. Dual IL-17A/F blockade important. Abstr #LB0001 @RheumNow

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

#EULAR2026 POS0440 1-Year Open Label Extension Study of 6-monthly Inebilizumab, a CD19 depleter in #IgG4 disease: -No flare in INEB group; 6% flare in PBO-INEB -10.9% serious infections -1 pt discontinued due to low IgG Interested to see longer-term safety data @RheumNow https://t.co/PPUw81T8DZ

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What’s in the pipeline for #psoriatic_arthritis treatment? A special focus on Tyk2 inhibitors WIN session at #EULAR2026 @RheumNow https://t.co/dDJtmdx9xU

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
What is new in PsA? Dennis McGonagle's take at #EULAR2026 -a strong year for discovery in mechanisms of transition from PSO to PsA -publication of the first single cell atlas Enthesis -Better understanding of VTE mechanisms in JAKi in PsA -clinical aspects of Axial involvement https://t.co/v9cfn1y4fH

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Pts with AIIRD carry a high risk & burden of infection due to immune dysregulation, comorbids, GC/DMaRD use. As a rheumatologist, do you vaccinate your patients? #EULAR2026 @RheumNow

sheila RHEUMarampa ( View Tweet)

Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.

Dr. John Cush RheumNow ( View Tweet)

Prof. Pedro Machado shares this important slide on a quick guide to #vaccination in patients w/ RMDs highlighting which vaccines are universally indicated, accdg to epidemiologic risk and w/ CIs. #EULAR2026 @RheumNow https://t.co/JmTSC1uaph

Links:

sheila RHEUMarampa ( View Tweet)
#Vaccination in Rheum 📍Hold MTX 1-2wks post vax 📍For Bcell depleters, timing is based on B-cell repop’n kinetics, not fixed calendar intervals. THM: Assess vax need at dx, vax w/o delay #EULAR2026 @RheumNow https://t.co/6ptl8gyBLR

Links:

sheila RHEUMarampa ( View Tweet)
#EULAR2026 POS0438 In Part A (Phase II) RCT of Cutaneous #lupus, Litifilimab, a BDCA2 mAb improved CLASI-A vs PBO at Week 16. -Improvement as early as Week 4 -Low viral infections. Common AE: nasopharyngitis & headache. -Interested to see results of Part B (phase III) @RheumNow https://t.co/2zzHd9NgBi

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 Still undecided which session to attend? Please find my Conference Preview in the field of #SLE #lupus #biologics #targetedtherapy @RheumNow 😃 https://t.co/0m2p8mEgCQ https://t.co/C3xa5rPp9q

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 General Assembly is ON! Record-breaking 5'705 abstracts from 102 countries 187 scientific sessions ahead @rheumnow https://t.co/0kAqND11L7

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush RheumNow ( View Tweet)

Applying updated ACR guidelines in real life isn’t always straightforward. Two experts share insights on managing lupus nephritis beyond the textbook. Sponsored by Aurinia https://t.co/7NAJW3LoSM https://t.co/h5RHK290pD

Links:

Dr. John Cush RheumNow ( View Tweet)
Advanced Practice Rheum: Safety of Biologics and Novel Agents Dr. Jack Cush reviews safety of biologics and novel agents. This video is part of the Advanced Practice Rheum series. https://t.co/K5TiwFA0L2 https://t.co/XoFsTMnxPC

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×